2022
Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 670-679. PMID: 35614009, DOI: 10.1016/j.clml.2022.04.016.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHMA therapyPoor performance statusRate of hospitalizationSEER-Medicare databaseMyelodysplastic syndromeER visitsEarly discontinuationPerformance statusEmergency roomOlder agePredictors of discontinuationEmergency room visitsHigh-risk groupHigh economic burdenTreatment discontinuationExcess blastsMore hospitalizationsNew hospitalizationRefractory anemiaRoom visitsHigh riskDiscontinuationMD diagnosisAgent use
2021
Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes. Journal Of Clinical Oncology 2021, 39: 7043-7043. DOI: 10.1200/jco.2021.39.15_suppl.7043.Peer-Reviewed Original ResearchPoor performance statusPoor PSHigh-risk myelodysplastic syndromeHMA therapyReal-world studyMyelodysplastic syndromeProgression/unacceptable toxicityPills/dayRetrospective cohort studyTreatment-related factorsMultivariable logistic regressionDirect medical costsHigh-risk groupOne-thirdGCSF useMore comorbiditiesEarly discontinuationPerformance statusUnacceptable toxicityCohort studyExcess blastsMultivariable analysisRefractory anemiaSEER-MedicareSurvival outcomes
2020
Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes
Abel G, Klepin H, Magnavita E, Jaung T, Shallis R, Bahl N, Dellinger-Johnston R, Winer E, Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-139919.Peer-Reviewed Original ResearchECOG performance statusQuality of lifePerformance statusRBC transfusionMyelodysplastic syndromeExact testRed blood cell transfusionPatients' QOLDana-Farber Cancer InstituteTwo-sided Fisher's exact testMore RBC transfusionsPre-transfusion HbSetting of anemiaBlood cell transfusionHalf of patientsPost-transfusion increaseFisher's exact testCell transfusionPatient characteristicsUnstable anginaMedian HbMean ageTransfusion decisionsHb thresholdQoL assessment
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens
2015
Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer
Khan M, Wasim A, Mirrakhimov AE, McMahon BA, Judge DP, Chu LC, Banavali A, Zeidan AM. Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer. Case Reports In Oncological Medicine 2015, 2015: 163727. PMID: 25874142, PMCID: PMC4385621, DOI: 10.1155/2015/163727.Peer-Reviewed Case Reports and Technical NotesSmall cell lung cancerLimited stage small cell lung cancerModality approachCardiac transplantationHeart failureLung cancerLimited-stage small cell lung cancerLeft ventricular assistance deviceGood organ functionLeft ventricular devicesAdvanced heart failureExcellent performance statusSevere heart failureCell lung cancerVentricular assistance devicePerformance statusTherapeutic dilemmaCardiac supportTreatment optionsCase reportVentricular devicesSevere cardiomyopathyNew diagnosisOrgan functionTherapeutic paradigm
2013
Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza).
Zeidan A, Sun Z, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza). Journal Of Clinical Oncology 2013, 31: 7126-7126. DOI: 10.1200/jco.2013.31.15_suppl.7126.Peer-Reviewed Original Research
2012
Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.
Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178. DOI: 10.1182/blood.v120.21.3178.3178.Peer-Reviewed Original ResearchIron chelation therapyCongestive heart failureStudy cohortCardiac conduction disordersMedicare Part DTransfusion thresholdPerformance statusRed blood cellsMyelodysplastic syndromeRenal diseaseConduction disordersChelation therapyObservation periodHistory of CHFPart DCox proportional hazards modelICD-9-CM codesErythropoiesis-stimulating agentsCoronary artery diseaseEntire study cohortMyelodysplastic syndrome patientsEnd of studyProportional hazards modelUtilization patternsMedicare enrollment files